Although the PSA test is simple and safe and has an acceptable sensitivity and specificity, the implementation of PSA screening for PCa costs nearly double is associated with a high risk of overdiagnosis, and as a consequence presents the inevitable side effects that arise from unnecessary treatment [148]. The gene discussed is PROS1; the disease is posterior cortical atrophy.